Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-24-044749
Filing Date
2024-11-12
Accepted
2024-11-12 16:05:49
Documents
41
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 643182
2 ex31-1.htm EX-31.1 17266
3 ex31-2.htm EX-31.2 17283
4 ex32-1.htm EX-32.1 8239
  Complete submission text file 0001493152-24-044749.txt   2535811

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE telo-20240930.xsd EX-101.SCH 17347
6 XBRL CALCULATION FILE telo-20240930_cal.xml EX-101.CAL 27782
7 XBRL DEFINITION FILE telo-20240930_def.xml EX-101.DEF 58302
8 XBRL LABEL FILE telo-20240930_lab.xml EX-101.LAB 163886
9 XBRL PRESENTATION FILE telo-20240930_pre.xml EX-101.PRE 127947
43 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 242121
Mailing Address 100 SE 2ND ST SUITE 2000 #1009 MIAMI FL 33131
Business Address 100 SE 2ND ST SUITE 2000 #1009 MIAMI FL 33131 786-396-6723
Telomir Pharmaceuticals, Inc. (Filer) CIK: 0001971532 (see all company filings)

EIN.: 872606031 | State of Incorp.: FL | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41952 | Film No.: 241447994
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)